Abdelaleem Mohamed, Ezzat Hossam, Osama Muhammed, Megahed Adel, Alaa Waleed, Gaber Ahmed, Shafei Ayman, Refaat Alaa
Armed Forces College of Medicine (AFCM), Cairo, Egypt.
Research Center, Misr International University (MIU), Cairo, Egypt.
Oncol Rev. 2019 Apr 17;13(1):411. doi: 10.4081/oncol.2019.411. eCollection 2019 Jan 14.
Drug repurposing is the idea of using an already approved drug for another disease or disorder away from its initial use. This new approach ensures the reduction in high cost required for developing a new drug in addition to the time consumed, especially in the tumor disorders that show an unceasing rising rate with an unmet success rate of new anticancer drugs. In our review, we will review the anti-cancer effect of some CNS drugs, including both therapeutic and preventive, by searching the literature for preclinical or clinical evidence for anticancer potential of central nervous system drugs over the last 8 years period (2010-2018) and including only evidence from Q1 journals as indicated by Scimago website (www.scimagojr.com). We concluded that Some Central Nervous system drugs show a great potential as anti-cancer in vitro, in vivo and clinical trials through different mechanisms and pathways in different types of cancer that reveal a promising evidence for the repurposing of CNS drugs for new indications.
药物重新利用是指将已获批准的药物用于其最初用途之外的其他疾病或病症。这种新方法确保了除了节省开发新药所需的高昂成本外,还能节省时间,特别是在肿瘤疾病方面,其发病率持续上升,而新型抗癌药物的成功率却未达预期。在我们的综述中,我们将通过检索过去8年(2010 - 2018年)期间关于中枢神经系统药物抗癌潜力的临床前或临床证据的文献,并仅纳入Scimago网站(www.scimagojr.com)所示的Q1期刊的证据,来综述一些中枢神经系统药物的抗癌作用,包括治疗和预防作用。我们得出结论,一些中枢神经系统药物在体外、体内和临床试验中通过不同机制和途径,在不同类型癌症中显示出巨大的抗癌潜力,这为中枢神经系统药物用于新适应症的重新利用提供了有前景的证据。